Close Menu

Why We Need to Rethink the Regs

Premium

Robert Oldham says pharmacogenomics and current FDA rules aren’t compatible

Robert Oldham is CEO of Cancer Therapeutics of Augusta, Ga. He was previously director of oncology at Vanderbilt University Medical Center and director of the Biological Response Modifiers Program at the National Cancer Institute. He has published more than 400 articles and 13 books in the scientific literature. He can be reached at rko-nmt@mindspring.com.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.